30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Michael Wyzga

Track

Insider profile

Currently holds positions in X4 Pharmaceuticals Inc, Genzyme Corp, LogicBio Therapeutics Inc, OncoMed Pharmaceuticals Inc, Exact Sciences Corp and Gensight Biologics SA

Performance

Overall performance
0.6
Performance over holding periods
0.6
30 days 90 days 120 days
Average return -9% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chairman of the Board X4 Pharmaceuticals Inc March 13, 2019 -
Chief Financial Officer, Executive Vice President - Finance Genzyme Corp Nov. 1, 2008 -
Director LogicBio Therapeutics Inc Dec. 6, 2018 -
Independent Director OncoMed Pharmaceuticals Inc Oct. 14, 2013 -
Independent Director Exact Sciences Corp Feb. 9, 2015 -
Independent Director Gensight Biologics SA None -
Independent Director Akebia Therapeutics Inc Jan. 1, 2014 - Dec. 12, 2018
Independent Director Idenix Pharmaceuticals LLC March 1, 2012 - Aug. 5, 2014
President, Chief Executive Officer, Director Radius Health Inc Dec. 5, 2011 - Nov. 11, 2013
Michael Wyzga's trades of X4 Pharmaceuticals Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2023-08-22 2023-08-18
B Purchase
97,167 +0.4%
415.85
US$2,287,246 		97,167 +0.4% 415.85 US$2,287,246
2021-03-02 2021-02-26
PlS Planned sale
10,028 +42.7%
76.14
US$3,426,688 		10,028 +42.7% 76.14 US$3,426,688
2019-03-01 2019-02-28
PlS Planned sale
86,771 +11.3%
19.74
US$2,651,133 		86,771 +11.3% 19.74 US$2,651,133
2018-05-11 2018-05-10
PlS Planned sale
7,402 -40.3%
51.53
US$381,447 		7,402 -40.3% 51.53 US$381,447